2024-04-05 06:27:00
Diabetes drug protects the heart and combats obesity. The Italian study
It’s a diabetes drugbut also seems capable of protect the heart e di fight obesity. Is called tirzepatide (Tzt), it’s cool to debut on the US market and is the protagonist of one Italian study published in ‘Cardiovascular Diabetology’, signed by a team of researchers coordinated by Giuseppe Paolissoprofessor at the university UniCamillus of Rome and full professor of Internal Medicine atVanvitelli University of Naples.
The work also involved scientists fromUniversity of Salerno and of theInrca-Irccs of Ancona.
I study
Using a 3-step approach, the authors conducted a meta-analysis on the action of the Tzt at a cardiovascular level. In the laboratory they evaluated the in vitro cardiac protective effects on cardiac cells humans, then performed a bioinformatic analysis to confirm its mechanism of action.
“Powerful protective effects on the heart” have emerged, informs a note from UniCamillus.
“The results – we read – showed that tirzepatide reduces the probability of serious cardiovascular events, protecting cardiac cells from hypertrophy, fibrosis and cell death. Furthermore, it promotes cardiac contractility”. For the scholars, “the fact that it is an anti-diabetic drug makes this active ingredient doubly valid, considering that diabetic subjects are exposed to a greater risk of developing cardiovascular complications, including heart failure “.
The new drug
The tirzepatidenot yet available in Italy, “is a new drug for the treatment of type 2 diabetes – explains Paolisso – which however is also associated with notable anti-obesity effects, as well as protective against diabetes-induced heart disease. In our study we highlight that the cardioprotective effects of Tzt are linked to anti-inflammatory action e di counteracting oxidative stress and cardiac fibrosis.
Such effects make this new drug extremely topical and highly effective in the treatment of type 2 diabetes”, underlines the specialist who adds: “Everyone agrees that it will replace semaglutide”, the active ingredient of the anti-diabetes Ozempic and its slimming version Wegovy, “as a weight loss drug, and which could soon become the most effective principle for treating obesity and diabetes, as well as for prevent cardiovascular diseasesthe leading cause of death in type 2 diabetic patients”.
READ ALSO: Type 2 diabetes and Alzheimer’s are strongly connected: here’s why
#Diabetes #drug #discovered #good #heart #combats #obesity